Girihlet Announces Know-How Agreement with Mayo Clinic

Prospective study will provide training datasets to bolster ImmuneScanner, a tool for classifying responses to autoimmune therapies, to personalize treatments SAN FRANCISCO, Dec. 13, 2022 /PRNewswire/ -- Girihlet, an Oakland biotech that is developing ImmuneScanner, announced today that...

Click to view original post